Inhaltsseite: Home

Yield Enhancement

Swiss Classics

Wednesday, 1 September 2021 Reading time : 1 minute

Nestlé, Novartis, Roche and Zurich together account for well over half of the entire SMI. All four are rated "overweight" by ZKB Equity Research and are among the most popular underlyings for BRC due to their solid business models and stable price developments.

Callable Barrier Reverse Convertible on Nestlé, Novartis and Zurich

  • 7% coupon p.a.*
  • barrier at 69%*
  • 24 months maturity
  • Subscription period until September 2, 2021
  • Termsheet


Callable Barrier Reverse Convertible on Nestlé, Novartis and Roche

  • 7% coupon p.a.*
  • Barrier at 76%*
  • 12 months maturity
  • Subscription period ends on September 2, 2021
  • Termsheet

*indicative

 

Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen. 

Advanced search
/home/search/guidepost.html /home/general/quick_search_live.html

Current products

Ajax loading